No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ December 10, 2018 The ecDNA story – catching the mastermind behind cancer evolution February 20, 2023 Working to Close the Cancer Screening Gap Caused by COVID May 17, 2022 Tomorrow is National Prescription Drug Take-Back Day! April 29, 2022 Load more HOT NEWS “Supporting research is mission critical for me and always will be”... FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab ESMO Congress 2023, 20-24 October 2023 Madrid, Spain
